EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudiePragmatische StudieOpen Access · CC BY 4.0

Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT

Lucy E Bradshaw iD, Laura A Wyatt iD, Sara J Brown iD, Rachel H Haines iD, Alan A Montgomery iD, Michael R Perkin iD, Tracey H Sach iD, Sandra Lawton iD, Carsten Flohr iD, Matthew J Ridd iD, Joanne R Chalmers iD, Joanne Brooks iD und 13 weitere

Health Technology Assessment · 2024

DOI: 10.3310/rhdn9613 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Health Technology Assessment, 2024. Verfasst von Lucy E Bradshaw und 24 weiteren Autor:innen. Beteiligte Einrichtung: Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK. Hauptthemen laut MEDLINE: Emollients, Eczema, Cost-Benefit Analysis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic eczema is a common childhood skin problem linked with asthma, food allergy and allergic rhinitis that impairs quality of life.

Objectives

To determine whether advising parents to apply daily emollients in the first year can prevent eczema and/or other atopic diseases in high-risk children.

Design

A United Kingdom, multicentre, pragmatic, two-arm, parallel-group randomised controlled prevention trial with follow-up to 5 years.

Setting

Twelve secondary and four primary care centres.

Participants

Healthy infants (at least 37 weeks’ gestation) at high risk of developing eczema, screened and consented during the third trimester or post delivery.

Interventions

Infants were randomised (1 : 1) within 21 days of birth to apply emollient (Doublebase Gel®; Dermal Laboratories Ltd, Hitchin, UK or Diprobase Cream®) daily to the whole body (excluding scalp) for the first year, plus standard skin-care advice (emollient group) or standard skin-care advice only (control group). Families were not blinded to allocation. Main outcome measures Primary outcome was eczema diagnosis in the last year at age 2 years, as defined by the UK Working Party refinement of the Hanifin and Rajka diagnostic criteria, assessed by research nurses blinded to allocation. Secondary outcomes up to age 2 years included other eczema definitions, time to onset and severity of eczema, allergic rhinitis, wheezing, allergic sensitisation, food allergy, safety (skin infections and slippages) and cost-effectiveness.

Results

One thousand three hundred and ninety-four newborns were randomised between November 2014 and November 2016; 693 emollient and 701 control. Adherence in the emollient group was 88% (466/532), 82% (427/519) and 74% (375/506) at 3, 6 and 12 months. At 2 years, eczema was present in 139/598 (23%) in the emollient group and 150/612 (25%) in controls (adjusted relative risk 0.95, 95% confidence interval 0.78 to 1.16; p = 0.61 and adjusted risk difference −1.2%, 95% confidence interval −5.9% to 3.6%). Other eczema definitions supported the primary analysis. Food allergy (milk, egg, peanut) was present in 41/547 (7.5%) in the emollient group versus 29/568 (5.1%) in controls (adjusted relative risk 1.47, 95% confidence interval 0.93 to 2.33). Mean number of skin infections per child in the first year was 0.23 (standard deviation 0.68) in the emollient group versus 0.15 (standard deviation 0.46) in controls; adjusted incidence rate ratio 1.55, 95% confidence interval 1.15 to 2.09. The adjusted incremental cost per percentage decrease in risk of eczema at 2 years was £5337 (£7281 unadjusted). No difference between the groups in eczema or other atopic diseases was observed during follow-up to age 5 years via parental questionnaires.

Limitations

Two emollient types were used which could have had different effects. The median time for starting emollients was 11 days after birth. Some contamination occurred in the control group (< 20%). Participating families were unblinded and reported on some outcomes.

Conclusions

We found no evidence that daily emollient during the first year of life prevents eczema in high-risk children. Emollient use was associated with a higher risk of skin infections and a possible increase in food allergy. Emollient use is unlikely to be considered cost-effective in this context. Future research To pool similar studies in an individual patient data meta-analysis.

Trial registration

This trial is registered as ISRCTN21528841. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 12/67/12) and is published in full in Health Technology Assessment ; Vol. 28, No. 29. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EmollientsEczemaCost-Benefit AnalysisHumansFemaleMaleInfantInfant, NewbornUnited KingdomChild, PreschoolQuality-Adjusted Life YearsQuality of LifeTechnology Assessment, BiomedicalDermatitis, Atopic

Stichwörter der Autor:innen

ASTHMAATOPIC DERMATITISATOPIC ECZEMAECZEMAEMOLLIENTSFILAGGRINFOOD ALLERGYHAY FEVERINFLAMMATIONMOISTURISERSPREVENTIONRANDOMISED CONTROLLED TRIALSKIN BARRIERSKIN SENSITISATION

Substanzen

Emollients

Autor:innen und Institutionen

  • Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.
  • Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • Department of Dermatology, NHS Lothian, Edinburgh, UK.
  • Population Health Research Institute, St George's, University of London, London, UK.
  • Health Economics Group, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.
  • Rotherham NHS Foundation Trust, Rotherham, UK.

ORCID-Profile: Lucy E Bradshaw, Laura A Wyatt, Sara J Brown, Rachel H Haines, Alan A Montgomery, Michael R Perkin, Tracey H Sach, Sandra Lawton, Carsten Flohr, Matthew J Ridd, Joanne R Chalmers, Joanne Brooks, Richard Swinden, Eleanor J Mitchell, Stella Tarr, Nicola Jay, Kim S Thomas, Hilary Allen, Michael J Cork, Maeve M Kelleher, Eric L Simpson, Stella T Lartey, Robert J Boyle, Hywel C Williams

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Bradshaw, L. E., Wyatt, L. A., Brown, S. J., Haines, R. H., Montgomery, A. A., Perkin, M. R., Sach, T. H., Lawton, S., Flohr, C., Ridd, M. J., Chalmers, J. R., Brooks, J., Swinden, R., Mitchell, E. J., Tarr, S., Jay, N., Thomas, K. S., Allen, H., Cork, M. J., …, & Williams, H. C. (2024). Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT. Health Technology Assessment. https://doi.org/10.3310/rhdn9613

Vancouver

Bradshaw LE, Wyatt LA, Brown SJ, Haines RH, Montgomery AA, Perkin MR, et al. Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT. Health Technology Assessment. 2024. doi:10.3310/rhdn9613

BibTeX
@article{Bradshaw2024,
  author = {Bradshaw, Lucy E and Wyatt, Laura A and Brown, Sara J and Haines, Rachel H and Montgomery, Alan A and Perkin, Michael R and Sach, Tracey H and Lawton, Sandra and Flohr, Carsten and Ridd, Matthew J and Chalmers, Joanne R and Brooks, Joanne and Swinden, Richard and Mitchell, Eleanor J and Tarr, Stella and Jay, Nicola and Thomas, Kim S and Allen, Hilary and Cork, Michael J and Kelleher, Maeve M and Simpson, Eric L and Lartey, Stella T and Davies-Jones, Susan and Boyle, Robert J and Williams, Hywel C},
  title = {Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT},
  journal = {Health Technology Assessment},
  year = {2024},
  doi = {10.3310/rhdn9613}
}
Kostenlos starten →